<SEC-DOCUMENT>0001104659-17-062738.txt : 20171018
<SEC-HEADER>0001104659-17-062738.hdr.sgml : 20171018
<ACCEPTANCE-DATETIME>20171018141002
ACCESSION NUMBER:		0001104659-17-062738
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20171002
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171018
DATE AS OF CHANGE:		20171018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			uniQure N.V.
		CENTRAL INDEX KEY:			0001590560
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36294
		FILM NUMBER:		171142442

	BUSINESS ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP
		BUSINESS PHONE:		1-339-970-7000

	MAIL ADDRESS:	
		STREET 1:		PAASHEUVELWEG 25A
		CITY:			AMSTERDAM
		STATE:			P7
		ZIP:			1105 BP

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	uniQure B.V.
		DATE OF NAME CHANGE:	20131030
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a17-24180_18k.htm
<DESCRIPTION>8-K
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported):&#160; <b>October&nbsp;2, 2017</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">uniQure N.V.</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Charter)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">The Netherlands</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-36294</font></b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or Other<br>   Jurisdiction of Incorporation)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission<br>   File Number)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer<br>   Identification No.)</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Paasheuvelweg 25a,</font></b><br>    <b>1105 BP Amsterdam, The Netherlands</b></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="bottom" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of Principal Executive   Offices)</font></p>    </td>
<td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.0%;">
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>    </td>   </tr>  </table>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area code: <b>+31-20-566-7394</b></font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former Name or Former Address, if Changed Since Last Report)</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:36.3pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:7.5pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:7.5pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:7.5pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-indent:7.5pt;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17 CFR<font size="1" style="font-size:3.0pt;">&#160; </font>240.13e-4(c))</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&nbsp;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&nbsp;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Emerging growth company </font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a)&nbsp;of the Exchange Act. </font><font face="Wingdings">x</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">
<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604548\24180-1-ba.htm',USER='109952',CD='Oct 18 21:07 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 8.01. Other Events</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release of uniQure N.V. dated October&nbsp;2, 2017 announcing company presentations at upcoming October&nbsp;conferences</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release of uniQure N.V. dated October&nbsp;6, 2017 announcing orphan drug designation for AMT-130 in Huntington&#146;s disease</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release of uniQure N.V. dated October&nbsp;18, 2017 announcing the presentation of new preclinical data on AMT-130 in Huntington&#146;s Disease at the ESGCT 25th Anniversary Congress in Berlin</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01</font></b><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Financial Statements and Exhibits</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Exhibits</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a17-24180_1ex99d1.htm#Exhibit99_1_083854" title="Click to goto ">Press   Release of uniQure N.V. dated October&nbsp;2, 2017 announcing company   presentations at upcoming October&nbsp;conferences</a></font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.2</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a17-24180_1ex99d2.htm#Exhibit99_2_085743" title="Click to goto ">Press   Release of uniQure N.V. dated October&nbsp;6, 2017 announcing orphan drug   designation for AMT-130 in Huntington&#146;s disease</a></font></p>    </td>   </tr>
<tr>
<td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.3</font></p>    </td>
<td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.5%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="93%" valign="top" style="padding:0in 0in 0in 0in;width:93.76%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;"><a href="a17-24180_1ex99d3.htm#Exhibit99_3_085718" title="Click to goto ">Press   Release of uniQure N.V. dated October&nbsp;18, 2017 announcing the   presentation of new preclinical data on AMT-130 in Huntington&#146;s Disease at   the ESGCT 25th Anniversary Congress in Berlin</a></font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">2<a name="PB_2_203548_9856"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\109952\17-24180-1\task8604548\24180-1-ba.htm',USER='109952',CD='Oct 18 21:07 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;text-indent:27.5pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">UNIQURE N.V.</font></b></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: October&nbsp;18, 2017</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>    </td>
<td width="46%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/S/ MATTHEW KAPUSTA</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Matthew Kapusta</font></p>    </td>   </tr>
<tr>
<td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.84%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="46%" valign="top" style="padding:0in 0in 0in 0in;width:46.16%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Executive Officer</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">3<a name="PB_3_203626_5335"></a></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\109952\17-24180-1\task8604548\24180-1-ba.htm',USER='109952',CD='Oct 18 21:07 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a17-24180_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>


<html>
<head>



  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1<a name="Exhibit99_1_083854"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Announces Company Presentations at Upcoming October&nbsp;Conferences</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct.&nbsp;02, 2017 (GLOBE NEWSWIRE) &#151; uniQure N.V. (NASDAQ:QURE) a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced company presentations at the following conferences taking place in October:</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Alliance for Regenerative Medicine (ARM) 2017 Cell&nbsp;&amp; Gene Meeting on the Mesa, October&nbsp;4 - 6 2017, at the Estancia La Jolla Hotel&nbsp;&amp; Spa in La Jolla, California.</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Jonathan Garen, chief business officer, will present a corporate overview on Wednesday, October&nbsp;4<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2017 at 3:30 p.m.&nbsp;PDT. The live webcast can be accessed through the link displayed in the&nbsp;Investor section&nbsp;of the uniQure website. The webcast replay will be available for at least two weeks following the live event.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">European Society of Gene&nbsp;&amp; Cell Therapy (EGSCT) 25</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">th</font></b><b>&nbsp;Anniversary Congress, October&nbsp;17 - 20, 2017, at the BCC Berlin in Berlin, Germany.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Members of the uniQure research&nbsp;&amp; development team will be presenting new data focused on the progress and optimization of uniQure&#146;s lead programs in gene therapy:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Title:&nbsp;</b><i>AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in Huntington disease mouse models&nbsp;</i><br>  <b>Session Title:&nbsp;</b>1b - Ocular and Central Nervous System Gene and Cell Therapy I&nbsp;<br>  <b>Date and Time:&nbsp;</b>Wednesday, October&nbsp;18<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2017, from 8:30 - 10:40 am CET</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Title:&nbsp;</b><i>Engineered AAV capsids are successfully produced through the innovative approach of combining directed evolution and the BEVS expression system.&nbsp;</i><br>  <b>Poster and Date:&nbsp;</b>P347 - Wednesday, October&nbsp;18<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2017.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Title:&nbsp;</b><i>Development and characterization of MFP-inducible GeneSwitch system for AAV5 gene therapy of chronic diseases in the liver&nbsp;&nbsp;</i><br>  <b>Poster and Date:&nbsp;</b>P160 - Thursday, October&nbsp;19<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2017</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">4</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">th</font></b><b>&nbsp;Animal Models of Neurodegenerative Disease Conference, October&nbsp;22 - 24, 2017, at Chateau Liblice, Czech Republic.</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Members of the uniQure research&nbsp;&amp; development team will be presenting new data focused on progress in technologies and development of animal models in gene therapy for Huntington&#146;s disease:</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Title:&nbsp;</b><i>Establishing proof-of-concept of gene therapy for Huntington&#146;s disease.</i><br>  <b>Date:&nbsp;</b>Tuesday, October&nbsp;24<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>, 2017, morning session.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604600\24180-1-mm.htm',USER='109952',CD='Oct 18 21:30 2017' -->

<br clear="all" style="page-break-before:always;">
<div style="font-family:Times New Roman;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt 1.0in;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><b>Title:&nbsp;</b><i>AAV-mediated delivery in large animals.&nbsp;</i><br>  <b>Date:&nbsp;</b>Monday, October&nbsp;23<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">rd</font>, 2017, afternoon session.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington&#146;s disease and cardiovascular diseases.&nbsp;www.uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Maria E. Cantor</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Eva M. Mulder</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Malone</font></b>&nbsp;</p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: 339-970-7536</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +31 20 240 6103</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct:&nbsp; 339-970-7558&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile:&nbsp; 617-680-9452</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: +31 6 52 33 15 79</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile:&nbsp; 339-223-8541&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">m.cantor@uniQure.com&nbsp; &nbsp; &nbsp; &nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e.mulder@uniQure.com&nbsp; &nbsp; &nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">t.malone@uniQure.com</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604600\24180-1-mm.htm',USER='109952',CD='Oct 18 21:30 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>a17-24180_1ex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.2<a name="Exhibit99_2_085743"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="250" height="63" src="g241801moi001.jpg"></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Announces FDA Orphan Drug Designation for</font></b></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">AMT-130 in Huntington&#146;s disease</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">~ <i>First Investigational Gene Therapy in Huntington&#146;s Disease to Receive Designation ~</i></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lexington, MA and Amsterdam, the Netherlands,</font></b> October&nbsp;6, 2017 &#151; uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that AMT-130, its proprietary gene therapy candidate&nbsp;for Huntington&#146;s disease, has received Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). There are currently no approved medical treatments aimed at addressing the underlying cause of Huntington&#146;s disease, and AMT-130 has the potential to play a role in this area of high unmet medical need.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">ODD in the United States provides a special status for investigational drugs being developed for rare diseases considered to affect only up to 200,000 people in the U.S. The ODD programs offer product market exclusivity for up to seven years in the U.S. and ten years in the European Union following regulatory approval, along with tax and financial incentives for companies developing medicines for such orphan indications.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;Attaining orphan designation recognizes the potential that AMT-130 holds in delivering meaningful therapeutic benefit to patients suffering from this devastating disease,&#148; said Matthew Kapusta, chief executive officer of uniQure. &#147;It supports our ongoing development in Huntington&#146;s as we seek to bring the first gene therapy approach to this disease into the clinic next year.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">AMT-130 consists of an AAV5 vector carrying an artificial micro-RNA which silences the huntingtin gene. The therapeutic goal is to inhibit the production of the mutant protein. &nbsp;Using AAV vectors to deliver micro-RNAs directly into the brain represents a highly innovative approach to treating Huntington&#146;s disease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Huntington&#146;s disease</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Huntington&#146;s disease is a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioral abnormalities and cognitive decline, resulting in complete physical and mental deterioration over a 12- to 15-year period of time. The disease</font> is caused by the expansion of CAG trinucleotide in exon 1 of a multifunctional gene coding for protein called huntingtin. Despite the clear etiology, there are no therapies available to treat the disease, delay onset or slow progression of a patient&#146;s decline.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy &#151; single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington&#146;s disease and cardiovascular diseases.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">www.uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;look forward to&#148;, &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604600\24180-1-mo.htm',USER='109952',CD='Oct 18 21:30 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">success of any of our ongoing or planned clinical studies and/or development of our product candidates, and the scope of protection provided by our patent portfolio. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators&#146; clinical development activities, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in uniQure&#146;s Quarterly Report on Form&nbsp;10-Q filed on August&nbsp;8, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Contacts</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For Investors:</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For media:</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Maria E. Cantor</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Eva M. Mulder</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Malone</font></b></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: 339-970-7536</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +31 20 240 6103</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: 339-970-7558</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: 617-680-9452</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: +31 6 52 33 15 79</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: 339-223-8541</font></p>    </td>   </tr>
<tr>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">m.cantor@uniQure.com</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e.mulder@uniQure.com</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">t.malone@uniQure.com</font></p>    </td>   </tr>  </table>
</div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604600\24180-1-mo.htm',USER='109952',CD='Oct 18 21:30 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>a17-24180_1ex99d3.htm
<DESCRIPTION>EX-99.3
<TEXT>


<html>
<head>




  </head>
<body link=blue lang="EN-US">
<div style="font-family:Times New Roman;">
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.3<a name="Exhibit99_3_085718"></a></font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-weight:bold;"><img width="250" height="63" src="g241801mqi001.jpg"></font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Presents New Preclinical Data on AMT-130 in Huntington&#146;s Disease at the ESGCT 25</font></b><b><font size="1" style="font-size:6.5pt;font-weight:bold;position:relative;top:-3.0pt;">th</font></b><b>&#160;Anniversary Congress in Berlin</b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151; One-time Administration of AMT-130 Demonstrates</font> Survival Benefit and Functional Improvement of Huntington&#146;s Disease Symptoms in Preclinical Study &#151;</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#151; IND-enabling Toxicology Study Initiated &#151;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Lexington, MA and Amsterdam, the Netherlands,</font></b> October&nbsp;18, 2017 &#151; uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today presented new preclinical data on AMT-130, its proprietary gene therapy candidate for the treatment of Huntington&#146;s disease (HD), at the European Society of Gene and Cell Therapy (ESGCT) 25<font size="1" style="font-size:6.5pt;position:relative;top:-3.0pt;">th</font>&#160;Anniversary Congress in Berlin, Germany.</p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Data from the study demonstrate that following administration of AMT-130 in Huntington&#146;s disease mouse models, significant improvements in both motor-coordination and survival were observed, as well as a dose-dependent, sustained reduction in huntingtin protein. AMT-130 comprises an AAV5 vector carrying a DNA cassette encoding an engineered micro RNA (miHTT) that silences the human huntingtin protein.&#160; The study on functional improvement and sustained huntingtin lowering was performed by members of uniQure&#146;s research department in collaboration with Charles River Discovery Research Services, Finland.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are confident that the combination of suppression of neuronal dysfunction, improvement of Huntington&#146;s disease symptoms, extended survival and long-term huntingtin lowering observed in these studies, could translate into patient benefit and improve their quality of life,&#148; stated Sander van Deventer, M.D., Ph.D., chief scientific officer at uniQure. &#147;We have now begun our investigational new drug-enabling toxicology studies in rodents and non-human primates that will support an IND application for AMT-130 next year.&#148;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Preclinical Data Findings</font></u></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">This study builds on previous data generated at uniQure, demonstrating a long-term significant suppression of mutant huntingtin protein, the cause of Huntington&#146;s disease, after a single administration of AMT-130 in the Q175 mouse model of Huntington&#146;s disease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The current study was conducted in the rapidly progressing R6/2 mouse model of Huntington&#146;s disease, which is characterized by early onset of motor symptoms and a much reduced life-span. A single administration of AMT-130 into the striatum was followed by a significant improvement of motor symptoms including improved coordination on the rotarod (a rotating cylinder to test coordination, physical condition and motor planning) as well as a significantly increased median survival from 120 to 149 days, compared with the control group (<i>p</i> = 0.0270). The data also demonstrate a significant reduction in expression of mutant huntingtin protein.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The functional improvements observed in these preclinical studies helped support the Orphan Drug Designation granted to AMT-130 by the U.S. Food and Drug Administration earlier this month and reinforce that huntingtin-lowering gene therapy for Huntington&#146;s disease could modify the course of this devastating disease.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About Huntington&#146;s Disease</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Huntington&#146;s disease is a rare, inherited neurodegenerative disorder that leads to loss of muscle coordination, behavioral abnormalities and cognitive decline, resulting in complete physical and mental deterioration over a 12- to 15-year period of time. The disease is caused by an autosomal dominant</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604548\24180-1-mq.htm',USER='109952',CD='Oct 18 21:08 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">mutation, a cytosine-adenine-guanine (CAG) expansion, in the first exon of the huntingtin gene leading to a non-functional, aggregation prone mutated protein. Despite the clear etiology, there are no therapies available to treat the disease, delay onset, or slow progression of a patient&#146;s decline.</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About uniQure</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">uniQure is delivering on the promise of gene therapy &#151; single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington&#146;s disease and cardiovascular diseases. www.uniQure.com</font></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Forward-Looking Statements</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;look forward to&#148;, &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;will,&#148; &#147;would&#148; and similar expressions. Forward-looking statements are based on management&#146;s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, the development of our gene therapy product candidates, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates, and the scope of protection provided by our patent portfolio. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators&#146; clinical development activities, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading &#147;Risk Factors&#148; in uniQure&#146;s Quarterly Report on Form&nbsp;10-Q filed on August&nbsp;8, 2017. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.</font></i></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">uniQure Contacts:</font></b></p>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;">
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For Investors:</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">For Media:</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Eva M. Mulder</font></b></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Tom Malone</font></b></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: +31 20 240 6103</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Direct: 339-970-7558</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: +31 6 52 33 15 79</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mobile: 339-223-8541</font></p>    </td>   </tr>
<tr>
<td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.02%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">e.mulder@uniQure.com</font></p>    </td>
<td width="2%" valign="top" style="padding:0in 0in 0in 0in;width:2.0%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>    </td>
<td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.98%;">
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">t.malone@uniQure.com</font></p>    </td>   </tr>  </table>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade align="left" style="color:#010101;"></div>
</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\109952\17-24180-1\task8604548\24180-1-mq.htm',USER='109952',CD='Oct 18 21:08 2017' -->

</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g241801moi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g241801moi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ /H# 2(  A$! Q$!_\0
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M$=I=0L1C>GV:)"1_P)&'X5UO_!-3]K70O@'JVMZ#XHG-AI6N,EQ!?%&=+>9
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M=K9TW2:3W3O_ -NIMM^5K^1QX/Q,XHJ8[ZC0R1*JG;[2M_V\TDEYWMYGS?\
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MI5QX9TRW@DE#707[3<NJDK%'#G<"QP,M@ $GDC%<@G[$7Q99?^1%US_OA?\
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F#@H<E."LDOZU;>K?5GX;FN:XO,L7/'8Z?/4F[MO^M$EHDM$C_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g241801mqi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g241801mqi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  _ /H# 2(  A$! Q$!_\0
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M$=I=0L1C>GV:)"1_P)&'X5UO_!-3]K70O@'JVMZ#XHG-AI6N,EQ!?%&=+>9
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M=K9TW2:3W3O_ -NIMM^5K^1QX/Q,XHJ8[ZC0R1*JG;[2M_V\TDEYWMYGS?\
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MI5QX9TRW@DE#707[3<NJDK%'#G<"QP,M@ $GDC%<@G[$7Q99?^1%US_OA?\
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F#@H<E."LDOZU;>K?5GX;FN:XO,L7/'8Z?/4F[MO^M$EHDM$C_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
